India’s Sun Pharma Buys Ranbaxy As Daiichi Sankyo Exits In A $4 Billion Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
In a landmark deal that fits the “made-for-each-other” tag, India’s Sun Pharma agreed to acquire all of Ranbaxy in a $4 billion transaction. While Ranbaxy can hope for a fresh lease on life with tighter regulatory operations under Sun Pharma, analysts said Sun needed to go for a big catch to keep its growth momentum.